The goal of this study is to treat patients diagnosed with relapsed or refractory positive B cell lymphoma - positive for 2 or more target antigens - with CAR19.20.22 CAR T-cells. Based on the preclinical characteristics of the LTG2950, CAR19.20.22 tri-specific CAR T-cells the Investigators have developed the following hypotheses to be tested in our phase Ia clinical trial. The Investigators hypothesize that these novel CAR T-cells will show: * good safety and tolerability * a high degree of efficacy * very good persistence * an acceptable level of exhaustion
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [Safety and Tolerability]
Timeframe: From date of enrollment assessed up to 24 months
Efficacy Overall Response Rate in participants
Timeframe: From date of enrollment assessed up to 24 months
Change in CAR19.20.22 T-cell function assessed by multicolor ELISPOT assay using CD19/CD22 protein targets.
Timeframe: From date of enrollment assessed up to 24 months
Persistence of CAR19.20.22 T-cells in peripheral blood measured by qPCR vector copy number and flow cytometry enumeration of CD19 and CD22 CAR-expressing T-cells."
Timeframe: From date of enrollment assessed up to 24 months